Bone Marrow Transplantation - Table of Contents alert Volume 52 Issue 6

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 52, Issue 6 (June 2017) In this issue Reviews Special Report Original Articles Technical Report Letters to the Editor Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Reviews Top Cord blood transplantation: rewind to fast forward A Dahlberg and F Milano Bone Marrow Transplant 2017 52: 799-802; advance online publication, December 19, 2016; 10.1038/bmt.2016.336 Abstract | Full Text Clinical management of genital chronic GvHD B K Hamilton, O Goje, B N Savani, N S Majhail and P Stratton Bone Marrow Transplant 2017 52: 803-810; advance online publication, January 9, 2017; 10.1038/bmt.2016.315 Abstract | Full Text Special Report Top Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report OPEN J R Passweg, H Baldomero, P Bader, C Bonini, R F Duarte, C Dufour, A Gennery, N Kröger, J Kuball, F Lanza, S Montoto, A Nagler, J A Snowden, J Styczynski and M Mohty for the European Society for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant 2017 52: 811-817; advance online publication, March 13, 2017; 10.1038/bmt.2017.34 Abstract | Full Text Original Articles Top ACUTE LEUKEMIA Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry-based study M Yanada, S Kurosawa, T Kobayashi, Y Ozawa, H Kanamori, N Kobayashi, M Sawa, H Nakamae, N Uchida, H Hashimoto, T Fukuda, M Hirokawa, Y Atsuta and S Yano Bone Marrow Transplant 2017 52: 818-824; advance online publication, January 23, 2017; 10.1038/bmt.2016.358 Abstract | Full Text Allogeneic stem cell transplantation for refractory acute myeloid leukemia in pediatric patients: the UK experience P O'Hare, G Lucchini, M Cummins, P Veys, M Potter, S Lawson, A Vora, R Wynn, A Peniket, K Kirkland, R Pearce, J Perry and P J Amrolia on behalf of the British Society Of Bone Marrow Transplant (BSBMT) Clinical Trials Committee Bone Marrow Transplant 2017 52: 825-831; advance online publication, February 20, 2017; 10.1038/bmt.2017.3 Abstract | Full Text PLASMA CELL DISORDERS Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication A Arteche-López, A Kreutzman, A Alegre, P Sanz Martín, B Aguado, M González-Pardo, M Espiño, L M Villar, D García Belmonte, R de la Cámara and C Muñoz-Calleja Bone Marrow Transplant 2017 52: 832-838; advance online publication, April 3, 2017; 10.1038/bmt.2017.29 Abstract | Full Text Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma A P Nair, P Walker, A Kalff, K Bergin, J Hocking, S Avery, D J Curtis, S Patil, T Das, D Klarica, S Morgan, J Muirhead, M Gorniak, J Reynolds and A Spencer Bone Marrow Transplant 2017 52: 839-845; advance online publication, March 20, 2017; 10.1038/bmt.2017.37 Abstract | Full Text INHERITED AND GENETIC DISORDERS Changes in the incidence, patterns and outcomes of graft failure following hematopoietic stem cell transplantation for Hurler syndrome S H Lum, W P Miller, S Jones, K Poulton, W Ogden, H Lee, A Logan, D Bonney, T C Lund, P J Orchard and R F Wynn Bone Marrow Transplant 2017 52: 846-853; advance online publication, February 20, 2017; 10.1038/bmt.2017.5 Abstract | Full Text GRAFT SOURCE Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults Y Le Bris, T Guillaume, A Ménard, M Illiaquer, J Martin, S Malard, A Duquesne, P Peterlin, C Debord, N Robillard, M Eveillard, S Wuillème, J Delaunay, M Mohty, A Garnier, P Moreau, M C Béné and P Chevallier Bone Marrow Transplant 2017 52: 854-858; advance online publication, January 30, 2017; 10.1038/bmt.2016.364 Abstract | Full Text CELLULAR THERAPY Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation G M Dotoli, G C De Santis, M D Orellana, K de Lima Prata, S R Caruso, T R Fernandes, V A Rensi Colturato, A T Kondo, N Hamerschlak, B P Simões and D T Covas Bone Marrow Transplant 2017 52: 859-862; advance online publication, March 13, 2017; 10.1038/bmt.2017.35 Abstract | Full Text TRANSPLANT TOXICITIES Associations between levels of insulin-like growth factor 1 and sinusoidal obstruction syndrome after allogeneic haematopoietic stem cell transplantation S Weischendorff, K Kielsen, H Sengeløv, K Jordan, C H Nielsen, A E Pedersen, L P Ryder, A Juul and K G Müller Bone Marrow Transplant 2017 52: 863-869; advance online publication, April 24, 2017; 10.1038/bmt.2017.43 Abstract | Full Text Pre-transplant ferritin, albumin and haemoglobin are predictive of survival outcome independent of disease risk index following allogeneic stem cell transplantation L Chee, M Tacey, B Lim, A Lim, J Szer and D Ritchie Bone Marrow Transplant 2017 52: 870-877; advance online publication, May 15, 2017; 10.1038/bmt.2017.51 Abstract | Full Text GRAFT-VERSUS-HOST DISEASE Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC L Magro, J Gauthier, M Richet, M Robin, S Nguyen, F Suarez, J-H Dalle, T Fagot, A Huynh, M-T Rubio, R Oumadely, S Vigouroux, N Milpied, A Delcampe and I Yakoub-Agha Bone Marrow Transplant 2017 52: 878-882; advance online publication, February 20, 2017; 10.1038/bmt.2017.9 Abstract | Full Text INFECTIONS A new time-dependent approach for assessment of the impact of invasive aspergillosis shows effect on short- but not on long-term survival of patients with AML or high-risk MDS R J van de Peppel, P A von dem Borne, S le Cessie and M G J de Boer Bone Marrow Transplant 2017 52: 883-888; advance online publication, May 15, 2017; 10.1038/bmt.2017.71 Abstract | Full Text QOL AND PATIENTS' CARE Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: a survey of UK NHS-based programmes A Hamblin, D M Greenfield, M Gilleece, N Salooja, M Kenyon, E Morris, N Glover, P Miller, H Braund, A Peniket, B E Shaw and J A Snowden on behalf of the British Society of Blood and Marrow Transplantation (BSBMT)12 Bone Marrow Transplant 2017 52: 889-894; advance online publication, April 24, 2017; 10.1038/bmt.2017.67 Abstract | Full Text Technical Report Top CMV viral load in bronchoalveolar lavage for diagnosis of pneumonia in allogeneic hematopoietic stem cell transplantation L Iglesias, M M Perera, L Torres-Miñana and M J Pena-López Bone Marrow Transplant 2017 52: 895-897; advance online publication, February 20, 2017; 10.1038/bmt.2017.11 Abstract | Full Text Letters to the Editor Top Untreated donor specific antibodies against HLA are associated with poor outcomes in peripheral blood haploidentical hematopoietic cell transplantation J Zou, R Romee, M Slade, D Phelan, J Keller, T Mohanakumar and B J Grossman Bone Marrow Transplant 2017 52: 898-901; advance online publication, February 20, 2017; 10.1038/bmt.2017.7 Full Text The 'HLA conundrum in bone marrow transplantation': correct interpretation of anti-HLA antibodies in haploidentical donor selection A L Dias, S Hashmi, W Hogan, N Baig, L Wakefield, J Kreuter and M J Gandhi Bone Marrow Transplant 2017 52: 902-904; advance online publication, February 20, 2017; 10.1038/bmt.2017.13 Full Text Non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide cures the first adult patient with congenital dyserythropoietic anemia A Oh, P R Patel, N Aardsma, S R Mehendale, R Chowdhery, K Sweiss and D Rondelli Bone Marrow Transplant 2017 52: 905-906; advance online publication, March 20, 2017; 10.1038/bmt.2017.17 Full Text A short tale of blood, kidney and brain: BK virus encephalitis in an allogeneic stem cell transplant recipient C Bourlon, S Alamoudi, D Kumar, A Viswabandya, S Thyagu, F V Michelis, D (D-H) Kim, J H Lipton, H A Messner and U Deotare Bone Marrow Transplant 2017 52: 907-909; advance online publication, February 20, 2017; 10.1038/bmt.2017.18 Full Text Late recurrence of autologous GvHD in a myeloma patient: a myth or diagnostic challenge? N El-Jurdi, M Ueda, L Jia and H Lazarus Bone Marrow Transplant 2017 52: 910-912; advance online publication, March 20, 2017; 10.1038/bmt.2017.20 Full Text Successful HLA haploidentical HSCT with post-transplant cyclophosphamide in Wiskott–Aldrich syndrome P Kreetapirom, S Hongeng, W Manuyakorn, U Anurathapan, S Pakakasama, N Sirachainan and B S Andersson Bone Marrow Transplant 2017 52: 913-914; advance online publication, March 13, 2017; 10.1038/bmt.2017.25 Full Text Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet? H Lee, P Duggan, P Neri, J Tay, N J Bahlis and V H Jimenez-Zepeda Bone Marrow Transplant 2017 52: 915-917; advance online publication, March 13, 2017; 10.1038/bmt.2017.28 Full Text Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT J El-Cheikh, R Massoud, E Fares, N Kreidieh, R Mahfouz, M Charafeddine, M A Kharfan-Dabaja and A Bazarbachi Bone Marrow Transplant 2017 52: 918-921; advance online publication, April 3, 2017; 10.1038/bmt.2017.31 Full Text Developing quality assurance for pediatric autologous stem cell transplants in England: results of a 3-year national audit of activity and engraftment by treatment centre D A Morgenstern, P Gray, A Prudhoe, M Watts and K Wheeler Bone Marrow Transplant 2017 52: 922-925; advance online publication, March 13, 2017; 10.1038/bmt.2017.32 Full Text High angiopoietin-2 and suppression of tumorigenicity-2 levels correlate with onset of sinusoidal obstructive syndrome—implication for the utility of serial biomarker monitoring A T Nunes, P Jain, D E Kleiner, N N Shah, P Anandi, F Chinian, P Muranski, M Battiwalla, A J Barrett and S Ito Bone Marrow Transplant 2017 52: 926-928; advance online publication, March 13, 2017; 10.1038/bmt.2017.38 Full Text Advance care planning and end-of-life care for patients with hematologic malignancies who die after hematopoietic cell transplant E E Eckhert, K L Schoenbeck, D Galligan, L M McNey, J Hwang and G N Mannis Bone Marrow Transplant 2017 52: 929-931; advance online publication, March 13, 2017; 10.1038/bmt.2017.41 Full Text Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning M Bill, M Jentzsch, J Grimm, K Schubert, T Lange, M Cross, G Behre, V Vucinic, W Pönisch, G-N Franke, D Niederwieser and S Schwind Bone Marrow Transplant 2017 52: 932-935; advance online publication, April 3, 2017; 10.1038/bmt.2017.42 Full Text Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy S W Wong, D Larivee, M Warner, K A Sprague, T Fogaren and R L Comenzo Bone Marrow Transplant 2017 52: 936-937; advance online publication, April 10, 2017; 10.1038/bmt.2017.47 Full Text Haploidentical stem cell transplantation with CD3+-/CD19+- depleted peripheral stem cells for patients with advanced stage sickle cell disease and no alternative donor: results of a pilot study J Foell, B Pfirstinger, K Rehe, D Wolff, E Holler and S Corbacioglu Bone Marrow Transplant 2017 52: 938-940; advance online publication, April 24, 2017; 10.1038/bmt.2017.49 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Bone Marrow Transplantation. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.